Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Nizar J. Bahlis, Jeffrey A. Zonder, Lionel Karlin, Torben Plesner, Laura París, Tomasz Wróbel, Vânia Hungria, Britta Besemer, Edvan Crusoé, Trine Silkjær, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark‐David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wróblewski, Alba Tuozzo, Robin Carson, Thierry Facon (2025). Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. , 66(14), DOI: https://doi.org/10.1080/10428194.2025.2561117.
Article22 days agoEfficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients
Enrique M. Ocio, Aurore Perrot, Jesús F. San Miguel, Lionel Karlin, Joaquín Martínez‐López, Sara Bringhen, Paula Rodríguez‐Otero, Mohamad Mohty, Robert Orlowski, Meletios A Dimopoulos, Xavier Leleu, María‐Victoria Mateos, Philippe Moreau, Sandrine Macé, Ercem Kodas, Christina Tekle, Umer Khan, Corina Oprea, Thierry Façon (2025). Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-2267.
Article22 days agoImpact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results
Meletios A Dimopoulos, Matthew C. Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, Hans Guenter Derigs, Hyeon Seok Eom, Karim Belhadj, Pascal Lenain, Richard H. van der Jagt, Sophie Rigaudeau, Mamoun Dib, R. Hall, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Guang Chen, Jennifer Marek, Annette Ervin‐Haynes, Thierry Façon (2014). Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results. , 124(21), DOI: https://doi.org/10.1182/blood.v124.21.2112.2112.
Article22 days agoCYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Meletios A Dimopoulos, Katja Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, Laurent Garderet, Michèle Cavo, Иванова , Adrían Alegre, Joaquín Martínez‐López, C. I Chen, A. Spencer, Stefan Knop, NJ Bahlis, C. Renner, Xiaoyan Yu, Kelvin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel (2014). CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. , 99
Article22 days agoMM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH
Jesús F. San Miguel, Katja Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, Laurent Garderet, Michèle Cavo, Иванова , Adrían Alegre, Joaquín Martínez‐López, C. I Chen, C. Renner, NJ Bahlis, Xiaoyan Yu, T Teasdale, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios A Dimopoulos (2014). MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH. , 99
Article22 days ago